BioMarin acquires Amicus Therapeutics for $4.8bn

Pharmaceutical Technology

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

pharminent April 28, 2026 (Last updated: April 28, 2026)

Pharmaceutical Technology

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

Related Stories